LEADER 05203nam 2200613Ia 450 001 9910877830003321 005 20200520144314.0 010 $a1-281-93939-0 010 $a9786611939397 010 $a0-470-69687-7 010 $a0-470-69688-5 035 $a(CKB)1000000000552962 035 $a(EBL)366784 035 $a(OCoLC)437234398 035 $a(SSID)ssj0000225840 035 $a(PQKBManifestationID)11202225 035 $a(PQKBTitleCode)TC0000225840 035 $a(PQKBWorkID)10234196 035 $a(PQKB)11672332 035 $a(MiAaPQ)EBC366784 035 $a(EXLCZ)991000000000552962 100 $a20080604d2008 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aPractical lipid management $econcepts and controversies /$fPeter P. Toth, Kevin C. Maki 210 $aChichester, West Sussex, UK ;$aHoboken, NJ $cWiley-Blackwell$d2008 215 $a1 online resource (264 p.) 300 $aDescription based upon print version of record. 311 $a0-470-05690-8 320 $aIncludes bibliographical references and index. 327 $aPractical Lipid Management; Contents; Foreword; Preface; Acknowledgements; Chapter 1 Epidemiology of Lipids, Lipid Management and Risk for Coronary Heart Disease: An Overview; 1.1 Early History of Cardiovascular Epidemiology; 1.2 Lipid Risk Factors are Central to Efforts at CHD Prevention; 1.3 LDL-C and CHD Risk; 1.4 LDL-C Lowering and CHD Risk Reduction; 1.5 Other Atherogenic Lipoproteins: Atherogenic Remnants; 1.6 HDL-C and CHD Risk; 1.7 Trends in Lipids and Lipid Management in the USA 327 $a1.8 The National Cholesterol Education Program Evaluation Project Using Novel E-Technology (NEPTUNE) II SurveyControversy: Should a Measure of Atherogenic Lipoprotein Particle Number be used in Risk Assessment And/Or to Evaluate the Response to Lipid Therapy?; Chapter 2 Vascular Biology and Atherogenesis; 2.1 Introduction; 2.2 Arterial Structure; 2.3 Endothelial Cell Function and Dysfunction; 2.4 The Role of Monocytes and Lymphocytes; 2.5 Atheromatous Plaques; Chapter 3 Detection, Evaluation, and Treatment Goals for Lipid Disorders in Adults 327 $a3.1 Matching Aggressiveness of Treatment to Absolute Risk3.2 Screening for Dyslipidemias; 3.3 Risk Stratification; 3.4 Steps in the Risk Stratification Process - Major Risk Categories; 3.5 Tips for Calculating the Framingham Risk Score; 3.6 Subcategories for Consideration of More Aggressive Optional Treatment Goals; 3.7 Very High Risk Patients, Optional LDL-C Goal <70 mg dl-1; 3.8 Moderately High Risk Patients, OPTIONAL LDL-C Goal <100 mg dl-1; 3.9 Treatment Goals for Patients with Elevated Triglycerides; 3.10 Triglycerides and HDL-C as Targets for Therapy 327 $aControversy: Should Treatment Guidelines Include Targets for the Total/HDL Cholesterol Ratio?Chapter 4 Therapeutic Lifestyle Changes in the Management of Lipid Disorders and the Metabolic Syndrome; 4.1 Nature and Nurture in the Development of CHD Risk Factors; 4.2 Lifestyle Factors as Determinants of CHD Risk in Populations; 4.3 Within Country Variations in Lifestyle and CHD Risk; 4.4 The Metabolic Syndrome; 4.5 Therapeutic Lifestyle Changes; 4.6 The TLC Diet; 4.7 Dietary Adjuncts: Viscous Fibers and Plant Sterol/Stanol Products; 4.8 Physical Activity and Weight Reduction 327 $a4.9 Smoking Cessation4.10 Importance of Allied Health Professionals; Chapter 5 Management of Elevated Low-Density Lipoprotein Cholesterol; 5.1 Relationship between LDL-C and Risk for Cardiovascular Events; 5.2 Clinical Trial Support for Very Aggressive LDL-C Reduction for Those at Highest Risk; 5.3 Genetic Disorders Associated with Elevated LDL-C; 5.4 Atherogenic Impact of LDL-C; 5.5 Management of Elevated LDL-C; 5.6 Summary; Controversy: How Low Should We Go?; Controversy: Risks and Bene.ts of High-Dose Statin Therapy Versus Combination Lipid Drug Therapy 327 $aControversy: Do the Benefits of Low-Density Lipoprotein Cholesterol Reduction Depend Strictly on "How Low You Go" or also on "How You Get There"? 330 $aLipid management is a key part of medical practice, affecting the prevention and treatment of several diseases, including diabetes, cardiovascular disease and stroke. A practical text on the clinical management of dyslipidemias, Practical Lipid Management balances conceptual development and pathophysiology with a straightforward approach to the identification and treatment of abnormalities in lipid metabolism. The book explores the role of novel risk markers in clinical practice, summarizes the current guidelines for lipid management, and offers a critical and systematic approach to i 606 $aHyperlipidemia$xTreatment 606 $aCoronary heart disease$xPrevention 615 0$aHyperlipidemia$xTreatment. 615 0$aCoronary heart disease$xPrevention. 676 $a616.3/997 700 $aToth$b Peter P$01343554 701 $aMaki$b Kevin C$01729521 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910877830003321 996 $aPractical lipid management$94192957 997 $aUNINA